Tirzepatide
Injection or Sublingual
Many people struggle to lose weight despite doing everything right. You may be eating better, staying active, and still feel stuck in the same cycle of losing and regaining weight. Hunger stays high, cravings return, and it becomes harder to stay consistent over time. Over time, this can make progress feel less predictable and harder to maintain.
Tirzepatide is part of a doctor-supervised program designed to support appetite regulation and provide a more structured, consistent approach under medical guidance.
Provider-directed dose and schedule
Purchase Options
Purchase Options
Purchase Options
Purchase Options
How It Works
Tirzepatide works by acting on more than one pathway involved in appetite. It targets signals that influence hunger and how the body handles food. This broader activity may help reduce appetite while supporting more consistent intake patterns throughout the day. This may help reduce how often you think about food and make eating feel more controlled.
The program uses a structured dosing approach that is adjusted by a licensed provider based on your response. This helps guide use while aiming to limit unwanted effects.
Understanding Your Options
Both Semaglutide and Tirzepatide are used in structured, provider-reviewed programs designed to support appetite regulation.
Semaglutide works on a single pathway involved in hunger and fullness and is often selected by patients starting with GLP-1 treatment.
Tirzepatide works on multiple pathways related to appetite and may be chosen by those looking for a broader approach.
Both options follow a guided dosing plan and can be adjusted over time based on your response. Semaglutide is often selected as a starting point for patients new to GLP-1 treatment, while Tirzepatide may be considered for a broader pathway approach.
Why This Approach Works
Tirzepatide combines a multi-pathway approach with structured clinical guidance. Instead of relying on trial and error, dosing and progression are adjusted based on your response. This helps create a more controlled and consistent process over time.
Who It May Be For
Adults struggling with ongoing hunger or cravings
Weight loss that is inconsistent or hard to maintain
Frequent food focus throughout the day
Looking for a structured medical approach
Prefer guidance from a licensed provider
Support & Ongoing Care
With RestartRX, you are not managing this process on your own. A licensed provider reviews your plan, and support is available if adjustments are needed. You will receive clear guidance on dosing, use, and next steps.
Product Options
Typical Dosing Overview
Treatment typically begins at a lower dose and may increase gradually over time based on tolerance and provider review.
Because of this, the amount of medication needed may change depending on where you are in the program.
Dosing is measured weekly and may change over time based on your response. The amount provided may vary depending on your dosing plan and where you are in the program.
Your provider will confirm your dosing plan before treatment is finalized.
Sublingual Option
Absorbed under the tongue as a non-injection option.
Used as part of a daily routine based on your provider-reviewed plan.
Concentration Details
All injectable options contain:
Tirzepatide 10 mg/mL, Glycine 5 mg/mL, Vitamin B12 500 mcg/mL
Sublingual drops contain:
Tirzepatide 3 mg/mL
Selection Guidance
Choose the option closest to your current weekly dose, or select a starter option if you are new to treatment.
Your provider will review and adjust your plan as needed before treatment is finalized.
Each option is designed to typically support a 4-week treatment cycle at the specified weekly dose. Dosing is based on mg per week, and the vial size is selected to align with common dosing ranges. Most treatment plans follow this four-week structure, though your provider may adjust your dose or schedule.
Formulation Notes
These options are compounded formulations prepared by a licensed pharmacy. Compounded medications are made to meet specific prescribing needs and may differ from commercially available products.
Tirzepatide may be provided as an injection or a sublingual formulation. Injections are given under the skin and are commonly used when a structured, consistent dosing routine is preferred. Sublingual options are taken by mouth and absorbed under the tongue, and may be preferred by those who want to avoid injections.
Sublingual formulations are compounded and are not FDA-approved as specific drug products. This is common for personalized formulations prepared by compounding pharmacies.
Some injection options include glycine and vitamin B12 as part of the formulation. Glycine is an amino acid commonly used in compounded blends, and vitamin B12 is often included in wellness-focused formulations.
Both options are used within a structured plan. Your provider will help determine which option is appropriate based on your preferences, medical history, and treatment plan.
Safety Summary
Tirzepatide (Injection)
Common Side Effects
- Nausea
- Constipation
- Stomach discomfort
- Diarrhea
Do Not Use If
You have a personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine
Neoplasia syndrome type 2 (MEN2).
Serious risks include pancreatitis and gallbladder disease; see full safety information.
Treatment requires review by a licensed clinician. Not all patients will qualify for therapy. Prescriptions are issued at the discretion of the evaluating provider. Results are not guaranteed. This information is for educational purposes and does not replace medical advice. Review full
safety details before starting treatment.
Full Medication Safety Information
Active Ingredient
Tirzepatide
Common Side Effects
- Nausea
- Constipation
- Vomiting
- Diarrhea
- Acid reflux
- Injection site irritation
Serious Risks
- Pancreatitis
- Gallbladder disease
- Kidney injury
- Severe allergic reaction
- Possible thyroid C-cell tumors
Who Should Not Use
- Personal or family history of MTC
- MEN2 syndrome
- Type 1 diabetes
- Diabetic ketoacidosis
Important Warnings
This medication slows stomach emptying and may affect anesthesia during procedures.
Important Safety Note
Do not use with other GLP-1 medications unless directed by your clinician.
Tell your clinician about all medications and supplements you take.
FDA Status
Tirzepatide is FDA-approved. Compounded versions may be prescribed.
This therapy may be provided as a compounded formulation and is not FDA-approved as a specific drug product.
Tirzepatide (Sublingual)
Common Side Effects
- Nausea
- Constipation
- Diarrhea
- Vomiting
Do Not Use If
You have a personal or family history of medullary thyroid cancer (MTC) or Multiple Endocrine
Neoplasia syndrome type 2 (MEN2).
Serious risks include pancreatitis and gallbladder disease; see full safety information.
Treatment requires review by a licensed clinician. Not all patients will qualify for therapy. Prescriptions are issued at the discretion of the evaluating provider. Results are not guaranteed. This information is for educational purposes and does not replace medical advice. Review full safety details before starting treatment.
Full Medication Safety Information
Active Ingredient
Tirzepatide
Common Side Effects
- Nausea
- Constipation
- Vomiting
- Diarrhea
Serious Risks
- Pancreatitis
- Gallbladder disease
- Kidney injury
- Severe allergic reaction
- Possible thyroid C-cell tumors
Who Should Not Use
- Personal or family history of MTC
- MEN2 syndrome
Important Warnings
This medication slows stomach emptying and may affect anesthesia.
Important Safety Note
Do not use with other GLP-1 medications unless directed by your clinician.
Tell your clinician about all medications and supplements you take.
FDA Status
Sublingual tirzepatide is not FDA-approved.
This therapy may be provided as a compounded formulation and is not FDA-approved as a specific drug product.
Some therapies may be prescribed for off-label use. Off-label prescribing is legal and common in medical practice when clinically appropriate.
Some people using GLP-1 medications notice occasional nausea during treatment. This can vary at different points in the plan, especially during dose changes. An add-on option may be considered if this becomes difficult to manage. This is the same type of medication commonly used in clinical settings for nausea related to treatments like GLP-1 medications.
Many patients do not need this add-on, but it is available if nausea becomes difficult to manage during treatment.
Ondansetron is a medication commonly used for nausea. It works on pathways in the body related to the nausea response. It is provided as an orally disintegrating tablet that dissolves in the mouth, allowing for simple use when symptoms occur.
This option is reviewed by a licensed provider and is not automatically included. Approval depends on your medical history, current medications, and whether this option is appropriate for your plan. This option is not required to start treatment and can be added if needed.
Typical Use Overview
- Ondansetron is used as an as-needed option for nausea.
- It is commonly taken when symptoms occur rather than on a fixed schedule.
- Your provider will review your selection and confirm if this option is appropriate based on your history and current medications.
How It's Used
Orally disintegrating tablets (ODT) dissolve in the mouth for easy use when needed.
Selection Guidance
This add-on is optional and not required to start treatment. If needed, your provider will review and approve this option based on your symptoms and medical history.
Start with a simple RestartRX medical review to see if this program is appropriate for you.